This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Abou-Raya, A., & Abou-Raya, S. (2006). Inflammation: A pivotal link between autoimmune diseases and atherosclerosis. Autoimmunity Reviews, 5(5), 331–337.
Abreu, M. R., Jakosky, A., Folgerini, M., Brenol, J. C., Xavier, R. M., & Kapczinsky, F. (2005). Neuropsychiatric systemic lupus erythematosus: Correlation of brain MR imaging, CT, and SPECT. Clinical Imaging, 29(3), 215–221.
Afeltra, A., Garzia, P., Mitterhofer, A. P., Vadacca, M., Galluzzo, S., & Del Porto, F., et al. (2003). Neuropsychiatric lupus syndromes: Relationship with antiphospholipid antibodies. [see comment]. Neurology, 61(1), 108–110.
Ainiala, H., Loukkola, J., Peltola, J., Korpela, M., & Hietaharju, A. (2001). The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology, 57(3), 496–500.
Alcocer-Varela, J., Aleman-Hoey, D., & Alarcon-Segovia, D. (1992). Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers. Lupus, 1(2), 111–117.
Allegri, F., Balestrieri, G., Cattaneo, R., Martinelli, M., Tincani, A., & Barcellini, W., et al. (1990). The plasma cofactor and anticardiolipin antibodies. Clinical & Experimental Rheumatology, 8(6), 613–615.
Appenzeller S., Rondina J. M., Li L. M., Costallat, T. L., & Cendes F. (2005) Cerebral and corpus callosum atrophy in systemic lupus erythematosus. Arthritis & Rheumatism, 52(9), 2783–2789.
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes (1999). Arthritis & Rheumatism, 42(4), 599–608.
Baraczka, K., Pozsonyi, T., Szongoth, M., Nekam, K., Megyeri, A., Balogh, Z., et al. (1999). A study of increased levels of soluble vascular cell adhesion molecule-1 (sVCAM-1) in the cerebrospinal fluid of patients with multiple sclerosis and systemic lupus erythematosus. Acta Neurologica Scandinavica, 99(2), 95–99.
Belmont, H. M., Abramson, S. B., & Lie, J. T. (1996). Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. interactions of inflammatory cells and activated endothelium. Arthritis & Rheumatism, 39(1), 9–22.
Bleiberg, J., Garmoe, W. S., Halpern, E. L., Reeves, D. L., & Nadler, J. D. (1997). Consistency of within-day and across-day performance after mild brain injury. Neuropsychiatry, Neuropsychology, & Behavioral Neurology, 10(4), 247–253.
Bleiberg, J., Kane, R. L., Reeves, D. L., Garmoe, W. S., & Halpern, E. (2000). Factor analysis of computerized and traditional tests used in mild brain injury research. Clinical Neuropsychologist, 14(3), 287–294.
Bleiberg, J., & Warden, D. (2005). Duration of cognitive impairment after sports concussion. Neurosurgery, 56(5), E1166.
Blohorn, A., Guegan-Massardier, E., Triquenot, A., Onnient, Y., Tron, F., & Borg, J. Y., et al. (2002). Antiphospholipid antibodies in the acute phase of cerebral ischaemia in young adults: A descriptive study of 139 patients. Cerebrovascular Diseases, 13(3), 156–162.
Brey, R. L. (2004). Management of the neurological manifestations of APS--what do the trials tell us? Thrombosis Research, 114(5–6), 489–499.
Brey, R. L., Hart, R. G., Sherman, D. G., & Tegeler, C. H. (1990). Antiphospholipid antibodies and cerebral ischemia in young people. Neurology, 40(8), 1190–1196.
Brey, R. L., Holliday, S. L., Saklad, A. R., Navarrete, M. G., Hermosillo-Romo, D., Stallworth, C. L., et al. (2002). Neuropsychiatric syndromes in lupus: Prevalence using standardized definitions. Neurology, 58(8), 1214–1220.
Brey, R. L., Stallworth, C. L., McGlasson, D. L., Wozniak, M. A., Wityk, R. J., Stern, B. J., et al. (2002). Antiphospholipid antibodies and stroke in young women. Stroke, 33(10), 2396–2400.
Campbell, A. L., Pierangeli, S. S., Wellhausen, S., & Harris, E. N. (1995). Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thrombosis & Haemostasis, 73(3), 529–534.
Cervera, R., Khamashta, M. A., Font, J., Sebastiani, G. D., Gil, A., & Lavilla, P., et al. (1999). Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. european working party on systemic lupus erythematosus. Medicine, 78(3), 167–175.
Cervera, R., Khamashta, M. A., Font, J., Sebastiani, G. D., Gil, A., & Lavilla, P., et al. (2003). Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine, 82(5), 299–308.
Cervera, R., Piette, J. C., Font, J., Khamashta, M. A., Shoenfeld, Y., & Camps, M. T., et al. (2002). Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis & Rheumatism, 46(4), 1019–1027.
Chinn, R. J., Wilkinson, I. D., Hall-Craggs, M. A., Paley, M. N., Shortall, E., Carter, S., et al. (1997). Magnetic resonance imaging of the brain and cerebral proton spectroscopy in patients with systemic lupus erythematosus. Arthritis & Rheumatism, 40(1), 36–46.
Costallat, L., Bertolo, M., & Appenzeller, S. (2001). The american college of rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes: Analysis of 527 patients. Lupus, 10(S1), S32.
Crowther, M. A., Ginsberg, J. S., Julian, J., Denburg, J., Hirsh, J., Douketis, J., et al. (2003). A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. New England Journal of Medicine, 349(12), 1133–1138.
Csepany, T., Bereczki, D., Kollar, J., Sikula, J., Kiss, E., & Csiba, L. (2003). MRI findings in central nervous system systemic lupus erythematosus are associated with immunoserological parameters and hypertension. Journal of Neurology, 250(11), 1348–1354.
Danchenko, N., Satia, J. A., & Anthony, M. S. (2006). Epidemiology of systemic lupus erythematosus: A comparison of worldwide disease burden. Lupus, 15(5), 308–318.
DeGiorgio, L. A., Konstantinov, K. N., Lee, S. C., Hardin, J. A., Volpe, B. T., & Diamond, B. (2001). A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nature Medicine, 7(11), 1189–1193.
del Zoppo, G. J., & Hallenbeck, J. M. (2000). Advances in the vascular pathophysiology of ischemic stroke. Thrombosis Research, 98(3), 73–81.
Denburg, S. D., Carbotte, R. M., Ginsberg, J. S., & Denburg, J. A. (1997). The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus. Journal of the International Neuropsychological Society, 3(4), 377–386.
Egerer, K., Feist, E., Rohr, U., Pruss, A., Burmester, G. R., & Dorner, T. (2000). Increased serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis in systemic lupus erythematosus. Lupus, 9(8), 614–621.
Esdaile, J. M., Abrahamowicz, M., Grodzicky, T., Li, Y., Panaritis, C., du Berger, R., et al. (2001). Traditional framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis & Rheumatism, 44(10), 2331–2337.
Futrell, N., Schultz, L. R., & Millikan, C. (1992). Central nervous system disease in patients with systemic lupus erythematosus. Neurology, 42(9), 1649–1657.
Galli, M., Comfurius, P., Maassen, C., Hemker, H. C., de Baets, M. H., van Breda-Vriesman, P. J., et al. (1990). Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet, 335(8705), 1544–1547.
Gaynor, B., Putterman, C., Valadon, P., Spatz, L., Scharff, M. D., & Diamond, B. (1997). Peptide inhibition of glomerular deposition of an anti-DNA antibody. Proceedings of the National Academy of Sciences of the United States of America, 94(5), 1955–1960.
Gharavi, A. E., & Pierangeli, S. S. (1998). Origin of antiphospholipid antibodies: Induction of aPL by viral peptides. Lupus, 7(Suppl 2), S52–S54.
Gharavi, A. E., Pierangeli, S. S., Colden-Stanfield, M., Liu, X. W., Espinola, R. G., & Harris, E. N. (1999). GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro. Journal of Immunology, 163(5), 2922–2927.
Gharavi, E. E., Chaimovich, H., Cucurull, E., Celli, C. M., Tang, H., & Wilson, W. A., et al. (1999). Induction of antiphospholipid antibodies by immunization with synthetic viral and bacterial peptides. Lupus, 8(6), 449–455.
Gonzalez-Crespo, M. R., Blanco, F. J., Ramos, A., Ciruelo, E., Mateo, I., Lopez Pino, M. A., et al. (1995). Magnetic resonance imaging of the brain in systemic lupus erythematosus. British Journal of Rheumatology, 34(11), 1055–1060.
Greco, C. M., Rudy, T. E., & Manzi, S. (2004). Effects of a stress-reduction program on psychological function, pain, and physical function of systemic lupus erythematosus patients: A randomized controlled trial. Arthritis & Rheumatism, 51(4), 625–634.
Haas, L. F. (1982). Stroke as an early manifestation of systemic lupus erythematosus. Journal of Neurology, Neurosurgery & Psychiatry, 45(6), 554–556.
Hallenbeck, J. M., Hansson, G. K., & Becker, K. J. (2005). Immunology of ischemic vascular disease: Plaque to attack. Trends in Immunology, 26(10), 550–556.
Hanly, J. G. (2001). Neuropsychiatric lupus. Current Rheumatology Reports, 3(3), 205–212.
Hanly, J. G., Hong, C., Smith, S., & Fisk, J. D. (1999). A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis & Rheumatism, 42(4), 728–734.
Hanly, J. G., Walsh, N. M., Fisk, J. D., Eastwood, B., Hong, C., Sherwood, G., et al. (1993). Cognitive impairment and autoantibodies in systemic lupus erythematosus. British Journal of Rheumatology, 32(4), 291–296.
Hanly, J. G., Walsh, N. M., & Sangalang, V. (1992). Brain pathology in systemic lupus erythematosus. Journal of Rheumatology, 19(5), 732–741.
Harrison, M., Ravdin, L., Volpe, B., Diamond, B., & Lockshin, M. (2004). Anti-NR2 antibody does not identify cognitive impairment in a general SLE population. Arthritis and Rheumatism, 50(9), S596.
Ho, K. T., Ahn, C. W., Alarcon, G. S., Baethge, B. A., Tan, F. K., Roseman, J., et al. (2005). Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. factors predictive of thrombotic events. Rheumatology, 44(10), 1303–1307.
Holliday, S. L., Navarrete, M. G., Hermosillo-Romo, D., Valdez, C. R., Saklad, A. R., Escalante, A., et al. (2003). Validating a computerized neuropsychological test battery for mixed ethnic lupus patients. Lupus, 12(9), 697–703.
Hughes, G. (1983). Thrombosis, abortion, cerebral disease and lupus anticoagulant. British Medical Journal, 187, 1088–1089.
Jara, L. J., Irigoyen, L., Ortiz, M. J., Zazueta, B., Bravo, G., & Espinoza, L. R. (1998). Prolactin and interleukin-6 in neuropsychiatric lupus erythematosus. Clinical Rheumatology, 17(2), 110–114.
Karassa, F. B., Ioannidis, J. P., Boki, K. A., Touloumi, G., Argyropoulou, M. I., Strigaris, K. A., et al. (2000). Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. American Journal of Medicine, 109(8), 628–634.
Kelley, V. R., & Wuthrich, R. P. (1999). Cytokines in the pathogenesis of systemic lupus erythematosus. Seminars in Nephrology, 19(1), 57–66.
Khamashta, M. A., Cuadrado, M. J., Mujic, F., Taub, N. A., Hunt, B. J., & Hughes, G. R. (1995). The management of thrombosis in the antiphospholipid-antibody syndrome. New England Journal of Medicine, 332(15), 993–997.
Komatsu, N., Kodama, K., Yamanouchi, N., Okada, S., Noda, S., Nawata, Y., et al. (1999). Decreased regional cerebral metabolic rate for glucose in systemic lupus erythematosus patients with psychiatric symptoms. European Neurology, 42(1), 41–48.
Kovacs, J. A., Urowitz, M. B., & Gladman, D. D. (1993). Dilemmas in neuropsychiatric lupus. Rheumatic Diseases Clinics of North America, 19(4), 795–814.
Kowal, C., DeGiorgio, L. A., Nakaoka, T., Hetherington, H., Huerta, P. T., Diamond, B., et al. (2004). Cognition and immunity; antibody impairs memory. Immunity, 21(2), 179–188.
Kozora, E., Laudenslager, M., Lemieux, A., & West, S. (2001). Inflammatory and hormonal measures predict neuropsychological functioning in systemic lupus erythematosus and rheumatoid arthritis patients. Journal of the International Neuropsychological Society, 7(6), 745–754.
Kozora E., Ellison MC., & West S. (2004). Reliability and validity of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus. Arthritis & Rheumatism, 51(5), 810–818.
Kozora E., Arciniegas D. B., Filley, C. M., Ellison M. C., West S. G., Brown M. S. & Simon J. H. (2005). Cognition, MRS neurometabolites, and MRI volymetrics in non-neuropsychiatric systemic lupus erythematosis: preliminary data. Cognitive and Behavioral Neurology, 18, 159–162.
Lanthier, S., Kirkham, F. J., Mitchell, L. G., Laxer, R. M., Atenafu, E., Male, C., et al. (2004). Increased anticardiolipin antibody IgG titers do not predict recurrent stroke or TIA in children. Neurology, 62(2), 194–200.
Leritz, E., Brandt, J., Minor, M., Reis-Jensen, F., & Petri, M. (2002). Neuropsychological functioning and its relationship to antiphospholipid antibodies in patients with systemic lupus erythematosus. Journal of Clinical & Experimental Neuropsychology: Official Journal of the International Neuropsychological Society, 24(4), 527–533.
Levine, S. R., Brey, R. L., Tilley, B. C., Thompson, J. L., Sacco, R. L., Sciacca, R. R., et al. (2004). Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA, 291(5), 576–584.
Libby, P. (2001). Managing the risk of atherosclerosis: The role of high-density lipoprotein. American Journal of Cardiology, 88(12A), 3 N–8 N.
Maier, S. F., Goehler, L. E., Fleshner, M., & Watkins, L. R. (1998). The role of the vagus nerve in cytokine-to-brain communication. Annals of the New York Academy of Sciences, 840, 289–300.
Manzi, S., Meilahn, E. N., Rairie, J. E., Conte, C. G., Medsger, T. A., Jr, Jansen-McWilliams, L., et al. (1997). Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the framingham study. American Journal of Epidemiology, 145(5), 408–415.
Matsuda, J., Gohchi, K., Gotoh, M., Tsukamoto, M., & Saitoh, N. (1994). Circulating intercellular adhesion molecule-1 and soluble interleukin 2-receptor in patients with systemic lupus erythematosus. European Journal of Haematology, 52(5), 302–303.
Matsuura, E., Igarashi, Y., Fujimoto, M., Ichikawa, K., & Koike, T. (1990). Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet, 336(8708), 177–178.
McGrath, H., Jr. (2005). Elimination of anticardiolipin antibodies and cessation of cognitive decline in a UV-A1-irradiated sustemic lupus erythematosis patient. Lupus, 14 (10), 859–861.
McLaurin, E. Y., Holliday, S. L., Williams, P., & Brey, R. L. (2005). Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology, 64(2), 297–303.
Menon, S., Jameson-Shortall, E., Newman, S. P., Hall-Craggs, M. R., Chinn, R., & Isenberg, D. A. (1999). A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis & Rheumatism, 42(4), 735–741.
Meroni, P. L., Del Papa, N., Raschi, E., Panzeri, P., Borghi, M. O., Tincani, A., et al. (1998). Beta2-glycoprotein I as a 'cofactor' for anti-phospholipid reactivity with endothelial cells. Lupus, 7(Suppl 2), S44–S47.
Mikdashi, J., & Handwerger, B. (2004). Predictors of neuropsychiatric damage in systemic lupus erythematosus: Data from the maryland lupus cohort. Rheumatology, 43(12), 1555–1560.
Miyakis, S., Giannakopoulos, B., & Krilis, S. A. (2004). Beta 2 glycoprotein I--function in health and disease. Thrombosis Research, 114(5–6), 335–346.
Miyakis, S., Lockshin, M. D., Atsumi, T., Branch, D. W., Brey, R. L., & Cervera, R., et al. (2006). International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis & Haemostasis, 4(2), 295–306.
Mok, C. C., Lau, C. S., & Wong, R. W. (2001). Neuropsychiatric manifestations and their clinical associations in southern chinese patients with systemic lupus erythematosus. Journal of Rheumatology, 28(4), 766–771.
Morris, R. G., Anderson, E., Lynch, G. S., & Baudry, M. (1986). Selective impairment of learning and blockade of long-term potentiation by an N-methyl-d-aspartate receptor antagonist, AP5. Nature, 319(6056), 774–776.
Navarrete, G., & Brey, R. (2000). Neuropsychiatric systemic lupus erythematosus. Current Treatment Options in Neurology, 2(5), 473–485.
Nencini, P., Baruffi, M. C., Abbate, R., Massai, G., Amaducci, L., & Inzitari, D. (1992). Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke, 23(2), 189–193.
Omdal, R., Brokstad, K., Waterloo, K., Koldingsnes, W., Jonsson, R., & Mellgren, S. I. (2005). Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. European Journal of Neurology, 12(5), 392–398.
Otte, A., Weiner, S. M., Peter, H. H., Mueller-Brand, J., Goetze, M., & Moser, E., et al. (1997). Brain glucose utilization in systemic lupus erythematosus with neuropsychiatric symptoms: A controlled positron emission tomography study. European Journal of Nuclear Medicine, 24(7), 787–791.
Ozawa, S., Kamiya, H., & Tsuzuki, K. (1998). Glutamate receptors in the mammalian central nervous system. Progress in Neurobiology, 54, 581–618.
Pierangeli, S. S., & Harris, E. N. (1994). Antiphospholipid antibodies in an in vivo thrombosis model in mice. Lupus, 3(4), 247–251.
Provenzale, J. M., Heinz, E. R., Ortel, T. L., Macik, B. G., Charles, L. A., & Alberts, M. J. (1994). Antiphospholipid antibodies in patients without systemic lupus erythematosus: Neuroradiologic findings. Radiology, 192(2), 531–537.
Reeves, D., Kane, R., & Winter, K. (1996). Automated neuropsychological assessment metrics (ANAM V3.11a/96) user's manual: Clinical and neurotoxicology subset (report no. NCRF-SR-96-01). San Diego CA: National Cognitive Foundation.
Reeves, D., Vleiberg, J., Roebuck-Spencer, T., Cernich, A., Schwab, K., Ivins, B., Salazar, A., Harvey, S., Brown, F, Warden, D. (2006). Reference values for performance on the Automated Neuropsychological Assessment Metrics V3.0 in an active duty military sample. Military Medicine, 171(10), 982–984.
Rhew, E. Y., & Ramsey-Goldman, R. (2006). Premature atherosclerotic disease in systemic lupus erythematosus--role of inflammatory mechanisms. Autoimmunity Reviews, 5(2), 101–105.
Rivest, C., Lew, R. A., Welsing, P. M., Sangha, O., Wright, E. A., Roberts, W. N., et al. (2000). Association between clinical factors, socioeconomic status, and organ damage in recent onset systemic lupus erythematosus. Journal of Rheumatology, 27(3), 680–684.
Roebuck-Spencer, T. M., Yarboro, C., Nowak, M., Takada, K., Jacobs, G., Lapteva, L., et al. (2006). Use of computerized assessment to predict neuropsychological functioning and emotional distress in patients with systemic lupus erythematosus. Arthritis & Rheumatism, 55(3), 434–441.
Roman, M. J., Shanker, B. A., Davis, A., Lockshin, M. D., Sammaritano, L., Simantov, R., et al. (2003). Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. New England Journal of Medicine, 349(25), 2399–2406.
Rosove, M. H., & Brewer, P. M. (1992). Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients. Annals of Internal Medicine, 117(4), 303–308.
Sailer, M., Burchert, W., Ehrenheim, C., Smid, H. G., Haas, J., Wildhagen, K., et al. (1997). Positron emission tomography and magnetic resonance imaging for cerebral involvement in patients with systemic lupus erythematosus. Journal of Neurology, 244(3), 186–193.
Schmidt, R., Auer-Grumbach, P., Fazekas, F., Offenbacher, H., & Kapeller, P. (1995). Anticardiolipin antibodies in normal subjects. neuropsychological correlates and MRI findings. Stroke, 26(5), 749–754.
Sfikakis, P. P., Charalambopoulos, D., Vayiopoulos, G., Oglesby, R., Sfikakis, P., & Tsokos, G. C. (1994). Increased levels of intercellular adhesion molecule-1 in the serum of patients with systemic lupus erythematosus. Clinical & Experimental Rheumatology, 12(1), 5–9.
Shovman, O., Gilburd, B., & Shoenfeld, Y. (2006). The role of inflammatory cytokines in the pathogenesis of systemic lupus erythematosus-related atherosclerosis: A novel target for treatment? Journal of Rheumatology, 33(3), 445–447.
Sibbitt, W. L.,Jr, Sibbitt, R. R., & Brooks, W. M. (1999). Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis & Rheumatism, 42(10), 2026–2038.
Singh, K., Gaiha, M., Shome, D. K., Gupta, V. K., & Anuradha, S. (2001). The association of antiphospholipid antibodies with ischaemic stroke and myocardial infarction in young and their correlation: A preliminary study. Journal of the Association of Physicians of India, 49, 527–529.
Spronk, P. E., Bootsma, H., Huitema, M. G., Limburg, P. C., & Kallenberg, C. G. (1994). Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. Clinical & Experimental Immunology, 97(3), 439–444.
Strater, R., Becker, S., von Eckardstein, A., Heinecke, A., Gutsche, S., Junker, R., et al. (2002). Prospective assessment of risk factors for recurrent stroke during childhood – a 5-year follow-up study. Lancet, 360(9345), 1540–1545.
Stoll, G., & Bendszus, M. (2006). Inflammation and atherosclerosis: Novel insights into plaque formation and destabilization. Stroke, 37(7), 1923–1932.
Sun, S. S., Liu, F. Y., Tsai, J. J., Yen, R. F., Kao, C. H., & Huang, W. S. (2003). Using 99mTc HMPAO brain SPECT to evaluate the effects of anticoagulant therapy on regional cerebral blood flow in primary antiphospholipid antibody syndrome patients with brain involvement-a preliminary report. Rheumatology International, 23(6), 301–304.
Tietjen, G. E., Day, M., Norris, L., Aurora, S., Halvorsen, A., Schultz, L. R., et al. (1998). Role of anticardiolipin antibodies in young persons with migraine and transient focal neurologic events: A prospective study. Neurology, 50(5), 1433–1440.
Toschi, V., Motta, A., Castelli, C., Paracchini, M. L., Zerbi, D., & Gibelli, A. (1998). High prevalence of antiphosphatidylinositol antibodies in young patients with cerebral ischemia of undetermined cause. Stroke, 29(9), 1759–1764.
Toubi, E., Khamashta, M. A., Panarra, A., & Hughes, G. R. (1995). Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. American Journal of Medicine, 99(4), 397–401.
Urowitz, M. B., Bookman, A. A., Koehler, B. E., Gordon, D. A., Smythe, H. A., & Ogryzlo, M. A. (1976). The bimodal mortality pattern of systemic lupus erythematosus. American Journal of Medicine, 60(2), 221–225.
van Goor, M. P., Alblas, C. L., Leebeek, F. W., Koudstaal, P. J., & Dippel, D. W. (2004). Do antiphospholipid antibodies increase the long-term risk of thrombotic complications in young patients with a recent TIA or ischemic stroke? Acta Neurologica Scandinavica, 109(6), 410–415.
Ward, M. M. (1999). Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis & Rheumatism, 42(2), 338–346.
Ward, M. M. (2004). Prevalence of physician-diagnosed systemic lupus erythematosus in the united states. J Women’s Health, 13(6), 713–718.
Weiner, S. M., Otte, A., Schumacher, M., Klein, R., Gutfleisch, J., Brink, I., et al. (2000). Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: Value of F-18 fluorodeoxyglucose PET. Annals of the Rheumatic Diseases, 59(5), 377–385.
West, S. G., Emlen, W., Wener, M. H., & Kotzin, B. L. (1995). Neuropsychiatric lupus erythematosus: A 10-year prospective study on the value of diagnostic tests. American Journal of Medicine, 99(2), 153–163.
Wu, J. T., & Wu, L. L. (2006). Linking inflammation and atherogenesis: Soluble markers identified for the detection of risk factors and for early risk assessment. Clinica Chimica Acta, 366(1–2), 74–80.
Zaccagni, H., Fried, J., Cornell, J., Padilla, P., & Brey, R. L. (2004). Soluble adhesion molecule levels, neuropsychiatric lupus and lupus-related damage. Frontiers in Bioscience, 9, 1654–1659.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Holliday, S.L., Brey, R.L. (2009). Neurovascular Consequences of Systemic Disease – Collagen Vascular Disease. In: Lazar, R., Festa, J. (eds) Neurovascular Neuropsychology. Springer, New York, NY. https://doi.org/10.1007/978-0-387-70715-0_15
Download citation
DOI: https://doi.org/10.1007/978-0-387-70715-0_15
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-70713-6
Online ISBN: 978-0-387-70715-0
eBook Packages: Behavioral ScienceBehavioral Science and Psychology (R0)